Comment.

Opinion. Presents the authors' view on historical preference for randomization inference and the regulatory benefit of a standardized approach to the analysis of clinical trial data, and focus in more detail on bias, proposing an alternative to E&F's estimate of treatment. Their objection related to the regulatory objective for a clinical trial to dictate a decision about a proposed therapy; Most important objection to controlling for compliance.